Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Non-Current Assets: 2014-2024

Historic Non-Current Assets for KalVista Pharmaceuticals (KALV) over the last 6 years, with Dec 2024 value amounting to $8.8 million.

  • KalVista Pharmaceuticals' Non-Current Assets was N/A to $8.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $8.8 million, marking a year-over-year change of. This contributed to the annual value of $9.7 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q4 2024, KalVista Pharmaceuticals' Non-Current Assets is $8.8 million, which was up 3.19% from $8.6 million recorded in Q4 2024.
  • Over the past 5 years, KalVista Pharmaceuticals' Non-Current Assets peaked at $10.5 million during Q3 2023, and registered a low of $3.4 million during Q4 2020.
  • Over the past 2 years, KalVista Pharmaceuticals' median Non-Current Assets value was $9.7 million (recorded in 2024), while the average stood at $9.5 million.
  • Examining YoY changes over the last 5 years, KalVista Pharmaceuticals' Non-Current Assets showed a top increase of 59.63% in 2020 and a maximum decrease of 19.18% in 2020.
  • Over the past 4 years, KalVista Pharmaceuticals' Non-Current Assets (Quarterly) stood at $3.4 million in 2020, then decreased by 5.80% to $3.7 million in 2021, then reached $10.1 million in 2023, then dropped by 15.52% to $8.8 million in 2024.
  • Its Non-Current Assets stands at $8.8 million for Q4 2024, versus $8.6 million for Q4 2024 and $8.6 million for Q3 2024.